Otsuka Of Japan's Abilify Drug Efficacy Questioned In Journal Item
This article was originally published in PharmAsia News
Executive Summary
Japanese drug maker Otsuka Pharmaceutical's clinical trials of its Abilify (aripiprazole) drug for treating bipolar disorder have been questioned in a published medical journal